Pradeep Bhandari

Pradeep Bhandari

Auto-generated profile, based on publicly available information

Pradeep Bhandari

Gastoenterology, Queen Alexandra Hospital, Portsmouth, UK

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in United European Gastroenterology Journal
Verified
Journal Article
Open access
PDF file
SSSharmila Subramaniam
Sharmila Subramaniam
KKKesavan Kandiah
Kesavan Kandiah
STSreedhari Thayalasekaran
Sreedhari Thayalasekaran
GLGaius Longcroft-Wheaton
Gaius Longcroft-Wheaton
PBPradeep Bhandari
Pradeep Bhandari
Background: Endoscopic resection is now commonly used for removal of early gastrointestinal lesions. However, the risk of the procedure may be heightened by intraprocedural or delayed bleeding. A novel, self‐assembling peptide (PuraStat®) was recently licensed for use as a haemostat.Objective: The aim of this study was to assess the efficacy and safety of this haemostat when used to control intraprocedural bleeding or to prevent delayed bleeding in endoscopic resection.Methods: PuraStat® was used on 100 patients undergoing endoscopic resection in a tertiary referral centre. The efficacy, safety, feasibility of use and delayed bleeding rates were measured.Results: Forty‐eight oesophageal, 31 colorectal, 11 gastric and 10 duodenal procedures were included. The mean lesion size was 3.7 cm and 30% of the patients were on antithrombotic therapy. Intraprocedural bleeding occurred in 64%. PuraStat® was an effective haemostat in 75% of these cases. Only a small amount was required for haemostasis (mean = 1.76 ml) and it took on average 69.5 seconds to stop a bleed. The delayed bleeding rate was 3%.Conclusions: PuraStat® is an effective haemostat for use in controlling bleeds during endoscopic resection. It is safe, easy to use and did not interfere with the procedure.

1 January 2012 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
GLGaius Mbbs Longcroft-Wheaton
Gaius Mbbs Longcroft-Wheaton
PBPradeep Md Bhandari
Pradeep Md Bhandari
Goals and Background: Conventional bowel preparation for afternoon colonoscopy requires an oral agent the day before the procedure. Bowel cleansing given only on the day of the colonoscopy has never been attempted. The aims of this study were to compare the efficacy of bowel cleansing, impact on activities of daily living (ADLs), side effects, and patient preference of a same-day regimen with a 2-day regimen. Study: A single-blinded, prospective cohort study. Patients were block recruited into 2 groups with the endoscopist blinded to the regimen. Group A: 3 sachets of sodium picosulphate given at 12:00 noon and at 05:00 PM the day before and at 8:00 AM on the morning of the procedure. Group B: 2 sachets of sodium picosulphate on the morning of the procedure at 07:00 and 10:00 AM. Patients completed a quality-of-life questionnaire investigating the side effects, impact on ADLs, and regimen preference. The main outcome measures were mucosal cleansing, impact on ADLs, side effects, and patient preference of the regimen. Results: A total of 227 patients underwent screening colonoscopy. There were 95 patients in group A and 132 in group B, all of whom were age and sex matched. Same-day preparation produced better mucosal cleansing (P=0.0046) with fewer side effects (P=0.002). Impact on ADLs was less with the same-day regimen (P<0.0001). Significantly more number of patients preferred the same-day preparation compared with the 2-day regimen (P=0.0147). Conclusions: Same-day bowel preparation is feasible, safe, and more effective than a split-dose regimen. It has fewer adverse events and is preferred by patients.

19 November 2020 in Gut
Verified
Journal Article
Open access
PDF file
KKKesavan Kandiah
Kesavan Kandiah
SSSharmila Subramaniam
Sharmila Subramaniam
STSreedhari Thayalasekaran
Sreedhari Thayalasekaran
FCFergus Jq Chedgy
Fergus Jq Chedgy
GLGaius Longcroft-Wheaton
Gaius Longcroft-Wheaton
PBPradeep Bhandari
Pradeep Bhandari
Background Longstanding colonic IBD increases the risk of developing colorectal cancer. The utility of chromoendoscopy with standard-definition white light technology has been established. However, the use of high-definition virtual chromoendoscopy (HDV) in colitis surveillance remains undefined. Objective To compare the performance of HDV (i-scan OE mode 2) with high-definition white light (HDWL) for detection of neoplasia in patients with IBD undergoing surveillance colonoscopy. Additionally, we assessed the utility of protocol-guided quadrantic non-targeted biopsies. Design A multioperator randomised controlled trial was carried out in two centres in the UK. Total of 188 patients (101 men, mean age 54) with longstanding ulcerative or Crohn’s colitis were randomised, prior to starting the surveillance colonoscopy, to using either HDV (n=94) or HDWL (n=94) on withdrawal. Targeted and quadrantic non-targeted biopsies were taken in both arms per-randomisation protocol. The primary outcome was the difference in neoplasia detection rate (NDR) between HDV and HDWL. Results There was no significant difference between HDWL and HDV for neoplasia detection. The NDR was not significantly different for HDWL (24.2%) and HDV (14.9%) (p=0.14). All intraepithelial neoplasia (IEN) detected contained low-grade dysplasia only. A total of 6751 non-targeted biopsies detected one IEN only. The withdrawal time was similar in both arms of the study; median of 24 min (HDWL) versus 25.5 min (HDV). Conclusion HDV and HDWL did not differ significantly in the detection of neoplasia. Almost all neoplasia were detected on targeted biopsy or resection. Quadrantic non-targeted biopsies have negligible additional gain. Trial registration number Clinical Trial.gov ID NCT02822352.

21 November 2011 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Closed access
PBPeter John Basford
Peter John Basford
PBPradeep Bhandari
Pradeep Bhandari
Duodenal polyps are a rare finding in patients presenting for gastroscopy, being found in 0.3–4.6% of cases. The majority of patients are asymptomatic. The most common lesions necessitating removal are duodenal adenomas which should be differentiated from other mucosal lesions such as ectopic gastric mucosa, and submucosal lesions such as carcinoids and gastrointestinal stromal tumours (GISTs). Adenomas can occur sporadically or as part of a polyposis syndrome. Both groups carry malignant potential but this is higher in patients with a polyposis syndrome. The majority of sporadic duodenal adenomas are flat or sessile and occur in the second part of the duodenum. Historically duodenal adenomas have been managed by radical surgery, which carried significant mortality and morbidity, or more conservative local surgical excision which resulted in high local recurrence rates. There is growing evidence for the use of endoscopic mucosal resection (EMR) techniques for treatment of sporadic nonampullary duodenal adenomas, with good outcomes and low complication rates. Endoscopic submucosal dissection (ESD) carries greater risk of complications and should be reserved for experts in this technique. Patients with sporadic duodenal adenomas carry an increased risk of colonic neoplasia and should be offered colonoscopy. The impact of endoscopic resection on the course of polyposis syndromes such as familial adenomatous polyposis (FAP) needs further study.

7 October 2011 in Diseases of the Esophagus
Verified
Journal Article
Closed access
PDF file
PBP. Bhandari
P. Bhandari
PKP. Kandaswamy
P. Kandaswamy
DCD. Cowlishaw
D. Cowlishaw
GLG. Longcroft-Wheaton
G. Longcroft-Wheaton

14 August 2012 in Endoscopy
Verified
Journal Article
Closed access
PDF file
GLG. Longcroft-Wheaton
G. Longcroft-Wheaton
JBJ. Brown
J. Brown
DCD. Cowlishaw
D. Cowlishaw
BHB. Higgins
B. Higgins
PBP. Bhandari
P. Bhandari
Background and study aims: The resolution of endoscopes has increased in recent years. Modern Fujinon colonoscopes have a charge-coupled device (CCD) pixel density of 650000 pixels compared with the 410000 pixel CCD in standard-definition scopes. Acquiring high-definition scopes represents a significant capital investment and their clinical value remains uncertain. The aim of the current study was to investigate the impact of high-definition endoscopes on the in vivo histology prediction of colonic polyps. Patients and methods: Colonoscopy procedures were performed using Fujinon colonoscopes and EPX-4400 processor. Procedures were randomized to be performed using either a standard-definition EC-530 colonoscope or high-definition EC-530 and EC-590 colonoscopes. Polyps of < 10 mm were assessed using both white light imaging (WLI) and flexible spectral imaging color enhancement (FICE), and the predicted diagnosis was recorded. Polyps were removed and sent for histological analysis by a pathologist who was blinded to the endoscopic diagnosis. The predicted diagnosis was compared with the histology to calculate the accuracy, sensitivity, and specificity of in vivo assessment using either standard- or high-definition scopes. Results: A total of 293 polyps of < 10 mm were examined – 150 polyps using the standard-definition colonoscope and 143 polyps using high-definition colonoscopes. There was no difference in sensitivity, specificity or accuracy between the two scopes when WLI was used (standard vs. high: accuracy 70 % [95 %CI 62 – 77] vs. 73 % [95 %CI 65 – 80]; P = 0.61). When FICE was used, high-definition colonoscopes showed a sensitivity of 93 % compared with 83 % for standard-definition colonoscopes (P = 0.048); specificity was 81 % and 82 %, respectively. Conclusions: There was no difference between high- and standard-definition colonoscopes when white light was used, but FICE significantly improved the in vivo diagnosis of small polyps when high-definition scopes were used compared with standard definition.